Drugs / autologous dendritic cell vaccination
autologous dendritic cell vaccination
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01291420 | May 2010 → Apr 2016 | breast cancer, colorectal neoplasm, glioblastoma, malignant mesothelioma +2 | University Hospital, Antwerp | Completed | No outcome recorded |
| Phase 1/2 | NCT00940004 | Jun 2009 → Nov 2014 | melanoma | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01431196 | Feb 2011 → Jun 2012 | breast cancer | Clinica Universidad de Navarra, Universidad de Navarra | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous dendritic cell vaccination | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01291420 ↗ |
| Modality | Cell therapy | “Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase” NCT00940004 ↗ |
| Route | Intravenous | “Dendritic cells are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months” NCT00940004 ↗ |